Form 8-K

8-K — Century Therapeutics, Inc.

Accession: 0001104659-26-094533

Filed: 2026-08-12

Period: 2026-08-12

CIK: 0001850119

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Results of Operations and Financial Condition

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — tm2622911d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2622911d1_ex99-1.htm)

EX-99.2 — EXHIBIT 99.2 (tm2622911d1_ex99-2.htm)

GRAPHIC (tm2622911d1_ex99-2img001.jpg)

GRAPHIC (tm2622911d1_ex99-2img002.jpg)

GRAPHIC (tm2622911d1_ex99-2img003.jpg)

GRAPHIC (tm2622911d1_ex99-2img004.jpg)

GRAPHIC (tm2622911d1_ex99-2img005.jpg)

GRAPHIC (tm2622911d1_ex99-2img006.jpg)

GRAPHIC (tm2622911d1_ex99-2img007.jpg)

GRAPHIC (tm2622911d1_ex99-2img008.jpg)

GRAPHIC (tm2622911d1_ex99-2img009.jpg)

GRAPHIC (tm2622911d1_ex99-2img010.jpg)

GRAPHIC (tm2622911d1_ex99-2img011.jpg)

GRAPHIC (tm2622911d1_ex99-2img012.jpg)

GRAPHIC (tm2622911d1_ex99-2img013.jpg)

GRAPHIC (tm2622911d1_ex99-2img014.jpg)

GRAPHIC (tm2622911d1_ex99-2img015.jpg)

GRAPHIC (tm2622911d1_ex99-2img016.jpg)

GRAPHIC (tm2622911d1_ex99-2img017.jpg)

GRAPHIC (tm2622911d1_ex99-2img018.jpg)

GRAPHIC (tm2622911d1_ex99-2img019.jpg)

GRAPHIC (tm2622911d1_ex99-2img020.jpg)

GRAPHIC (tm2622911d1_ex99-2img021.jpg)

GRAPHIC (tm2622911d1_ex99-2img022.jpg)

GRAPHIC (tm2622911d1_ex99-2img023.jpg)

GRAPHIC (tm2622911d1_ex99-2img024.jpg)

GRAPHIC (tm2622911d1_ex99-2img025.jpg)

GRAPHIC (tm2622911d1_ex99-2img026.jpg)

GRAPHIC (tm2622911d1_ex99-2img027.jpg)

GRAPHIC (tm2622911d1_ex99-2img028.jpg)

GRAPHIC (tm2622911d1_ex99-2img029.jpg)

GRAPHIC (tm2622911d1_ex99-2img030.jpg)

GRAPHIC (tm2622911d1_ex99-2img031.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2622911d1_8k.htm · Sequence: 1

false

0001850119

2026-08-12

0001850119

dei:FormerAddressMember

2026-08-12

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

August 12, 2026

Century Therapeutics, Inc.

(Exact name of registrant as specified in its

charter)

Delaware

001-40498

84-2040295

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification No.)

North 38th Street, 12th Floor

Philadelphia, Pennsylvania

19104

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including

area code: (267) 817-5790

North 38th Street, 11th Floor

Philadelphia,

Pennsylvania

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.

below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol

Name

of Exchange on Which Registered

Common Stock, par value $0.0001 per share

IPSC

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth

company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange

Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ¨

Item 2.02

Results of Operations and Financial Condition

On August

12, 2026, Century Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter

ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein

by reference.

The information contained in this Item 2.02 (including Exhibit 99.1)

is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended

(the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by

reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set

forth by specific reference in such filing.

Item 7.01

Regulation FD Disclosure

On August 12, 2026, the Company updated information

reflected in a slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by

reference. Representatives of the Company will use the updated presentation in various meetings with investors from time to time.

The information contained in this Item 7.01 (including Exhibit 99.2)

is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to

the liabilities of that section and shall not be deemed incorporated by reference in any filing under the Securities Act or the Exchange

Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits

Exhibit

No.

Document

99.1

Press Release of Century Therapeutics, Inc., dated August 12, 2026

99.2

Investor Presentation of Century Therapeutics, Inc., dated August 12, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf

by the undersigned hereunto duly authorized.

CENTURY THERAPEUTICS, INC.

By:

/s/ Brent Pfeiffenberger, Pharm.D., M.B.A.

Name:

Brent Pfeiffenberger, Pharm.D., M.B.A.

Title:

President, Chief Executive Officer and Chairman of

the Board of Directors

Date: August 12, 2026

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2622911d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Century Therapeutics Reports Second Quarter 2026 Financial

Results and Business Updates

· Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type

1 diabetes (T1D); IND submission on track for 4Q 2026

· CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing

success at clinical scale, advancing its potential as a functional cure for T1D

· Upcoming

oral presentations at European Association for the Study of Diabetes (EASD 2026) and Breakthrough

T1D® Clinical & Research Congress 2026 highlighting CNTY-813

· Company remains on track to advance CNTY-308, a CD19-targeted

CAR-iT cell therapy with Allo-EvasionTM 5.0 into the clinic

this year

· Cash runway into 1Q 2029 with cash, cash equivalents, and investments of $197.2 million as of June 30, 2026

PHILADELPHIA, August 12, 2026 ––

Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell

(iPSC)-derived cell therapies for autoimmune diseases, including T1D, and cancer, today reported financial results for the second quarter

ended June 30, 2026, and recent business highlights.

"We are executing with speed against key development

milestones, reinforcing our confidence in delivering on our ambition to transform diseases like T1D by creating functional cures at scale,"

said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. "With CNTY-813, our preclinical data at ADA

2026 continue to support its potential as a functional T1D cure, and we have established our Phase 1 manufacturing process, demonstrating

consistent product quality across independent batches. Our recent pre-IND meeting with the FDA builds on that progress yielding alignment

with the FDA on our nonclinical data package, manufacturing strategy, and proposed Phase 1/2 trial design, keeping CNTY-813's IND submission

on track for the fourth quarter of 2026. In addition, CNTY-308 remains on track to enter the clinic in 2026."

Second Quarter 2026 and Recent Highlights

Pre-IND meeting with the FDA supports regulatory and

initial clinical path for CNTY-813

· Following a recent pre-IND meeting with the FDA, Century remains on track to submit an IND for CNTY-813 in the fourth quarter of 2026.

· Century and the FDA reached general alignment on the nonclinical data package, the proposed Phase 1 manufacturing

process and the Phase 1/2 clinical trial design which includes alignment on:

o GLP toxicology study, which is ongoing and on track to support the planned submission.

o Phase 1 manufacturing process and testing plan that includes cell bank, intermediate, and final drug product release tests.

o Proposed Phase 1/2 clinical trial including dosing and patient eligibility criteria.

· New

preclinical data further support CNTY-813 as a potential functional cure for T1D;

data were presented at the 2026 American Diabetes Association (ADA) Scientific

Sessions in June (link to press release HERE).

Data demonstrated key advancements for CNTY-813 including:

o Durable in vivo glucose control maintained for more than eight months and immune evasion under allogeneic immune pressure without

immunosuppression.

o Consistent and scalable product quality and performance at Phase 1 clinical trial scale.

· IND submission remains on track for 4Q 2026, with initial clinical data expected in 2H 2027.

CNTY-813 Phase 1 manufacturing process established

· Century has established its Phase 1 clinical manufacturing bioreactor process for CNTY-813, demonstrating consistent process performance

and product quality, endocrine purity, and optimal islet cell content across independent batches run at the same scale intended for the

Phase 1 clinical trial.

CNTY-813 preclinical data selected for oral presentations

at congresses this fall

· 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD 2026; Milan, Italy; Presentation #225,

Paris Hall, October 2nd, 2026, 10-11 AM CEST)

· Breakthrough T1D® Clinical &

Research Congress 2026 (CRC 2026; Philadelphia, Pennsylvania; Presentation #341, Hall 1,

October 9th, 2026, 3:50- 4:50 PM EST)

· Both presentations will highlight CNTY-813, Century's iPSC-derived islet replacement therapy program engineered with Allo-Evasion™

5.0 for patients with T1D.

CNTY-308

clinical trial planned to initiate in 2026

· Century remains on track, after aligning on nonclinical, manufacturing and Phase 1 clinical trial parameters with health

authorities, to complete IND-enabling activities for CNTY-308,

a CD19-targeted CD4⁺/CD8⁺ αβ CAR-iT

cell therapy engineered with Allo-Evasion™ 5.0 for B-cell-mediated

diseases. CNTY-308 is anticipated to enter the clinic in 2026.

· Preclinical data showed functional comparability to primary CAR-T

cells, including target-driven proliferation, cytokine secretion, and

durable persistence. Collectively, these results and the expanding clinical validation of CAR-T therapy support Century’s confidence

that CNTY-308 could deliver autologous-like

benefits in an allogeneic, patient-centric format designed to broaden

access.

Second Quarter 2026 Financial Results

· Cash Position: Cash, cash equivalents, and investments were $197.2 million as of June 30, 2026, as compared to $117.1

million as of December 31, 2025. The company estimates its cash, cash equivalents, and investments as of June 30, 2026 will

support operations into 1Q 2029.

· Research and Development (R&D) Expenses: R&D expenses were $19.6 million for the quarter ended June 30, 2026,

compared to $26.9 million for the same period in 2025. The decrease was primarily the result of a reduction in personnel and a reduction

in facility costs as a result of our previously announced portfolio prioritization.

· General and Administrative (G&A) Expenses: G&A expenses were $5.8 million for the quarter ended June 30, 2026,

compared to $7.8 million for the same period in 2025.

· Net Income (Loss): Net (loss) was $34.6 million for the quarter ended June 30, 2026, compared to net (loss) of $32.5 million

for the same period in 2025.

About Century Therapeutics

Century Therapeutics (NASDAQ: IPSC) is a biotechnology company

advancing a pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies with the potential to meaningfully address autoimmune

diseases, including type 1 diabetes, and cancer. Century’s therapies are derived from its iPSC cell foundry and leverage its novel

immune evasion engineering technology, Allo-Evasion™. Century believes its approach to developing off-the-shelf cell therapies will

expand patient access and provide advantages over existing cell therapies which will ultimately advance the course of care. For more information

on Century Therapeutics, please visit www.centurytx.com and connect with us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within

the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements

contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions,

including but not limited to, statements our timing and expectations regarding our preclinical and clinical development programs, including

their planned development, therapeutic potential and market opportunity, ongoing and planned regulatory submissions and interactions,

the achievement of developmental milestones, corporate strategies, anticipated data readouts, and our financial resources and expected

cash runway are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors

that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements

expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,”

“might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,”

“anticipate,” “could,” “intend,” “target,” “project,” “contemplate,”

“believe,” “estimate,” “predict,” “forecast,” “potential” or “continue”

or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions.

We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends

that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as

of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted

or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future

product candidates through development activities, preclinical studies, and clinical trials; our ability to meet development milestones

on anticipated timelines; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials,

which may not be predictive of final results or the results of later-stage clinical trials; our ability to obtain clearance of our future

IND or CTA submissions and commence and complete clinical trials on expected timelines, or at all; our reliance on the maintenance of

certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood

of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of geopolitical issues,

trade disputes and tariffs, banking instability and inflation on our business and operations, supply chain and labor force; the performance

of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials

as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales

and marketing capabilities, if our product candidates are approved; our ability to recruit and maintain key members of management and

our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are

described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission

and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and

circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from

those projected in the forward-looking statements.

Moreover, we operate in a dynamic

industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict

all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise

any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or

otherwise.

For More Information:

Century Therapeutics

Douglas Carr

Senior Vice President, Finance

investor.relations@centurytx.com

Corey Davis, Ph.D.

LifeSci Advisors,

LLC 212-915-2577

cdavis@lifesciadvisors.com

Century

Therapeutics, Inc.

Condensed

Balance Sheets

(unaudited, in thousands)

June 30, 2026

December 31, 2025

Assets

Current assets

Cash and cash equivalents

$ 49,642

$ 61,853

Short-term investments

70,070

55,261

Prepaid expenses and other current assets

5,056

3,655

Total current assets

124,768

120,769

Property and equipment, net

34,482

50,026

Operating lease right-of-use assets

13,513

16,139

Long-term investments

77,477

—

Intangible assets

34,200

Other long-term assets

2,566

2,570

Total assets

$ 287,006

$ 223,704

Liabilities and stockholders’ equity

Current liabilities

Accounts payable

$ 4,823

$ 4,773

Accrued expenses and other liabilities

10,245

11,696

Contingent consideration liability, short-term

—

3,757

Total current liabilities

15,068

20,226

Operating lease liability, long term

34,626

40,241

Other long-term liabilities

666

—

Deferred tax liability

4,301

Total liabilities

54,661

64,768

Common stock

Additional paid-in capital

1,081,133

950,814

Accumulated deficit

(848,112 )

(791,917 )

Accumulated other comprehensive income

(694 )

Total stockholders’ equity

232,345

158,936

Total liabilities and stockholders’ equity

$ 287,006

$ 223,704

Century

Therapeutics, Inc.

Condensed consolidated

statements of operations

(unaudited, in thousands, except share and per share amounts)

Three Months Ended

Six Months Ended

June 30, 2026

June 30, 2025

June 30, 2026

June 30, 2025

Collaboration revenue

$ —

$ 109,164

Operating expenses

Research and development

19,595

26,859

36,700

53,439

General and administrative

5,787

7,805

12,366

16,212

Loss on lease component termination

11,145

—

11,145

—

Total operating expenses

36,527

34,664

60,211

69,651

Income (loss) from operations

(36,527 )

(34,664 )

(60,221 )

39,513

Interest income

1,982

2,010

4,001

4,431

Other income (expense), net

(5 )

113

Total other income

1,977

2,123

4,016

4,506

Net income (loss)

$ (34,550 )

$ (32,541 )

$ (56,195 )

$ 44,019

Unrealized loss on investments

(109 )

(222 )

(724 )

(241 )

Comprehensive income (loss)

$ (34,659 )

$ (32,763 )

$ (56,919 )

$ 43,778

Net income (loss) per common share, basic and diluted

(0.17 )

(0.38 )

(0.28 )

0.51

Weighted average common shares outstanding, basic

205,778,156

86,238,084

199,660,522

86,130,235

Weighted average common shares outstanding, diluted

205,778,156

86,238,084

199,660,522

86,207,666

EX-99.2 — EXHIBIT 99.2

EX-99.2

Filename: tm2622911d1_ex99-2.htm · Sequence: 3

Exhibit 99.2

Advancing Curative Medicines

Through Cell Engineering

August 2026

Forward-looking statements

This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995.

All statements contained in this presentation, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to,

statements our timing and expectations regarding our preclinical and clinical development programs, including their planned development, therapeutic potential and market

opportunity, ongoing and planned regulatory submissions and interactions, the achievement of developmental milestones, corporate strategies, anticipated data readouts, and our

financial resources and expected cash runway are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may

cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking

statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,”

“target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking

statements in this presentation are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and

financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this presentation

and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among

others: Our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; our ability to meet

development milestones on anticipated timelines; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials, which may not be

predictive of final results or the results of later-stage clinical trials; our ability to obtain clearance of our future Investigational New Drug (IND) or Clinical Trial Application (CTA)

submissions and commence and complete clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the

manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product

candidates; the impact of geopolitical issues, trade disputes and tariffs, banking instability and inflation on our business and operations, supply chain and labor force; the performance

of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers and manufacturers;

our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; our ability to recruit and

maintain key members of management and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are

described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these

forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results

could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may

emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to

publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Century Therapeutics: Advancing Curative Medicines Through Cell Engineering

The Cell Foundry: Enables scalable generation of

highly functional iPSC-derived therapies

Allo-EvasionTM 5.0: Leadership in immune-evasive

cell design

Integrated Know-How: Deep functional expertise

internally, integrated from discovery to

manufacturing and development

Foundational Platform Tech:

Engine to create and scale

cellular medicines

Targeting Functional Cures:

T1D and Autoimmune disease

Well Funded:

Multiple Anticipated Near-Term

Milestones

CNTY-813: iPSC-derived, immune-evasive islet

replacement therapy for type 1 diabetes

Islet replacement is clinically validated; CNTY-813 aims to

deliver this without chronic immunosuppression, at scale

Pipeline: Foundational technology powers:

• CNTY-308, an iPSC-derived, immune-evasive T cell

with potential across autoimmune disease

• Next-gen discovery programs across multiple cell types

and targets

Recent Funding

Oversubscribed $135M PIPE in early 2026 provides

runway into Q1 2029

Key Anticipated Near-Term Milestones

❑ CNTY-813 oral presentation at EASD 2026

❑ CNTY-813 IND submission expected 4Q 2026

❑ CNTY-308 expected in clinic in 2026

❑ Clinical data expected 2H 2027 for CNTY-813

Focused. Funded. Executing.

infusions in outpatient setting

Prioritized pipeline progressing toward the clinic

Allo-Evasion engineered in all programs

1. Agreement in place for an ongoing investigator sponsored trial (IST) for CNTY-101 by Professors Georg Schett and Andreas Mackensen at Friedrich-Alexander University Erlangen-Nürnberg.

Product Targets Indications Research IND-enabling Clinical

Priority Program

CNTY-813

Islet cells

(Allo-Evasion 5.0)

Islet

Transplantation Type 1 diabetes

Additional Programs1

CNTY-308

αβ iT (Allo-Evasion 5.0) CD19 B-cell-mediated autoimmune

diseases

Multiple

(Allo-Evasion 5.0) Multiple Not disclosed

Century executive team

Experienced leadership with a track record of driving innovation and success in cell therapy

Chad Cowan, PhD

Chief Scientific Officer

Brent Pfeiffenberger, PharmD, MBA

Chairman and

Chief Executive Officer

Greg Russotti, PhD

Chief Technology and Manufacturing Officer

Megan Bilson

Chief People Officer

Krista Kauppinen

General Counsel & Head of IP

Douglas Carr, CPA

Head of Finance

Principal Financial Officer

Elizabeth Devlin

Head of Development

New hope for T1D patients: CNTY-813

and the clinical case for islet replacement

iPSC-derived islet replacement therapy

engineered with Allo-Evasion 5.0

Significant unmet need in type 1 diabetes (T1D)

Despite insulin therapy, people living with T1D face a high risk of life-limiting complications

~9 million

people worldwide living with T1D1

Lifetime economic burden of T1D (US) estimated at

~$813 Billion2

T1D is associated with serious comorbidities

and complications3

1. Diabetes Res Clin Pract. 2025 Jul: 225:112277.doi: 10.1016/j.diabres.2025.112277. Epub 2025 May 22

2. https://www.liebertpub.com/doi/10.1089/dia.2019.0398

3. van den Boom L, Buchal G, Kaiser M, Kostev K. Multimorbidity among adult outpatients with type 1 diabetes in Germany. J Diabetes Sci Technol. 2022;16(1):152-160. doi:https://doi.org/10.1177/1932296820965261

Replacing lost insulin-producing islets has T1D curative potential

Supply and need for chronic immunosuppression limits broader use despite historical clinical validation

In T1D, islet cells are destroyed

Healthy islet cells

produce

insulin (green)

In T1D, islet cells

are destroyed by

patient’s own

immune system

Insulin independence following pancreatic islet transplantation

Islet transplantation provides a potentially curative therapy for T1D

Insulin independence achieved for one year in ~70% of patients receiving allogenic cadaveric

islet transplantation1

Source: Marfil-Garza et al. 2022; Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada

1. Approximately 1500 patients reported in https://www.citregistry.org/system/files/CITR%2012th%20Allograft%20Report_2025_Final.pdf

Stem-cell (SC) derived islets can restore islet function and address scalability

Chronic immunosuppression still limits broader use

Zimislecel (VX-880) is a SC-derived

insulin producing islet cell therapy1,2

10/12 patients receiving SC-derived islets were

exogenous insulin free at 12 months after a single dose3

1. ADA IR Presentation_v FINAL – Vertex Corporate website

2. Based on publicly available information

3. https://www.nejm.org/doi/10.1056/NEJMoa2506549?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed

VX-880 provides POC for SC-derived islet therapies but need for immunosuppression remains a challenge

Total Daily Insulin Dose (units/day)

Zimislecel is delivered by

infusion into the hepatic

portal vein

Steroid free

immunosuppression is

used to protect the

islet grafts

1 2

Century’s potential solution to T1D is leveraging iPSCs + ALLO-EVASIONTM 5.0

CNTY-813: scalable, iPSC-derived islet replacement therapy engineered to eliminate the need for immunosuppression

1. https://www.centurytx.com/wp-content/uploads/ASH_Welstead_Universal-Protection-of-Allogenic-T-Cells-Final.pdf

2. https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024013436/518079/Universal-Protection-of-Allogeneic-T-Cell

3. Peraro et al, Mol. Therapy 2021, 29(12), 3398-3409; https://pmc.ncbi.nlm.nih.gov/articles/PMC8636170

ALLO-EVASION 5.0: Evading cell-mediated and humoral responses

Protection from:

T cells

NK cells

Humoral

Immunity

Deletion of HLA-I

Deletion of HLA-II

3 Insertion of CD300a

TASR pan-NK inhibitory

ligand1, 2

4 Insertion of cell-surface

enzyme to degrade IgG

antibodies3

IgG Cleavage

Reduces Fc binding

and humoral activity

No HLA-I

Prevents recognition

by CD8+ cells T cells

No HLA-II

Prevents recognition

by CD4+ cells T cells

CD300a TASR Ligand

Inhibits NK cell

activation

1 NK Cell

3 Pan NK Inhibitory ligand

CIITA

KO (HLA-II)

CD4+T Cell

b2M KO

(HLA-I)

CD8+T Cell

✓ CD300a-TASR mimics

dying cell signal to

inhibit NK cells

✓ Sends a “no need to kill”

signal to NK cell

✓ CD300a expressed

across NK cell subsets

as well as monocytes

CD300a-TASR can protect Century’s iPSC-derived cells from NK cell killing

0 0 . 0 1 0 . 1 1

E:T Ratio 0.01 0.1 1

100 T Cell Survival (%) 0 0 0.01 0.1 1

No Cloak

CD300a TASR

CD47

HLA-I+

hours

Target (T)

Cell NK

Effector (E)

CD300a TASR outperformed CD47 and approaches unedited HLA-I+ protection levels

TASR

b2M

iPSC drug product

(live)

“No Need

To Kill”

NK Cell

TASR

CD300a

Dead/dying cell

NK Cell

“No Need

To Kill”

CD300a

CD300a detects disordered

membrane lipids

CD300a-TASR mimics

dead or dying cells CD300a consistently broadly expressed on NK cells

N = 45 Diverse PBMC Donors

CD300a NKG2A KIR

100

Inhibitory Receptor Expression on NK Cells

(n = 46 donors)

% of NK Cells

NK Donor 2 (2Cdom NK Donor 1 (2A )

dom) NK Donor 3 (2Adom)

https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024013436/518079/Universal-Protection-of-Allogeneic-T-Cell;

https://www.centurytx.com/wp-content/uploads/ASH_Welstead_Universal-Protection-of-Allogenic-T-Cells-Final.pdf

Immunoglobulin degrading protease

As a result, Century’s cells has been shown to

resist complement, antibody-directed killing,

and antibody-directed engulfment

Century T cells stably express IDP, an enzyme

that cleaves IgGs below the hinge

Century’s IgG degrading protease (IDP) protected cells from humoral immunity

Complement Dependent Cytotoxicity Antibody-Dependent Cellular Cytotoxicity Antibody-Dependent Cellular Phagocytosis Measure of Phagocytosis (Area under the curve)

Cells expressing

IDP showed less

phagocytosis in the

presence of an

antibody trigger

Cells → WT Century WT

Condition → +Ab +Ab -

Cells expressing

IDP showed

greater survival

GFP IdeStm

100

% Specific Lysis

✱✱✱✱

WT Century

Cells expressing

IDP showed less

lysis WT Gen 2.3

100

% Survival

✱

WT Century

Source: Company data on file

97% less lysis vs. WT 70% greater survival vs. WT 60% less phagocytosis, near baseline

CNTY-813: iPSC-derived islet replacement therapy with Allo-Evasion 5.0

Uniquely positioned to potentially deliver a successful T1D cell replacement therapy

• Glucose control in patients is important for resolving disease and reducing consequences of uncontrolled glucose

• A scalable drug product enables broader patient access, reduced COGs, and product consistency

• Broad NK subset evasion and protection from humoral responses to allogeneic islets or disease autoantibodies are critical for durable cure

Glucose Control Scalable Drug Product Free of Immune

Suppression

Protection Against Cellular

and Humoral Immune

Clearance

Cadaveric Islets

(+/- device) YES NO NO NO

SC-derived Islets YES YES NO NO

Allo-Engineered cadaveric islets -- NO YES NO

CNTY-813 iPSC Islets*

(Preclinical PoC) YES YES YES YES

J Clin Invest. 2004 Oct 1;114(7):877–883; N Engl J Med 2025;393:887-894; N Engl J Med 2025;393:858-868

In-house manufacturing at scale: A competitive advantage built from experience

Reproducible, scalable cell product from a single master cell bank to clinical supply

53,000 sq ft cGMP facility Single donor master cell banks Scalability with bioreactors

Built-for-purpose facility producing and

releasing cell therapy product

In-house team from development

through clinical supply — aligned

priorities, faster iteration, IP protected

Capacity and design suited for early

commercialization

Clonal origin enables a

well-characterized, homogeneous

product

Batch-to-batch consistency maintained

over the product lifetime

Multiple back up lines ensure

redundancy and next generation

product potential

Suspension-based iPSC differentiation

is scalable from research to clinical

manufacturing

Processes scalable to hundreds of

liters — Broad patient access, reduced

cost of goods

Batch-to-batch reproducibility

demonstrated across independent runs

Source: Company data on file.

A fully scalable, bioreactor-enabled differentiation process

yields mature, functional islets from engineered iPSCs for

Phase 1 clinical trials and beyond

Clinical candidate selected with Century’s Allo-Evasion 5.0

to protect cells from immune rejection and disease-related

autoantibodies

In vitro and in vivo data support potential to provide

functional cure without systemic immunosuppression

CNTY-813:

Islet function, immune-evasive engineering, and

scalable manufacturing

address key barriers for

T1D cell replacement

Generation of islets with a 29-day defined process

High purity and reproducible across batches

Consistent Differentiation

• Surpassed necessary

purity at every stage

• >95% Endocrine

• 50–60% Beta Cells

(Insulin Producing)

Stage 1:

Definitive Endoderm

97.3 (20)

Stage 4:

Pancreatic Progenitor II

98.2 (24)

Stage 6:

Islet Endocrine

95.9 (32)

Stage 6:

Beta Cell

Mean (n) 60.2 (32)

iPSC

Definitive

Endoderm

Stage 1

Primitive

Gut Tube

Stage 2

Pancreatic

Progenitor II

Stage 4

Endocrine

Stage 5

β Cell

Stage 6

Pancreatic

Progenitor I

Stage 3

• Dotted lines: Success criteria

• N are independent batches.

• Source: Company data on file

Phase 1 clinical manufacturing process established and executed from MCB across multiple

independent batches

MCB Thaw iPSC Expansion Bioreactor Differentiation Cryopreserved Intermediate Post-Thaw Maturation Final Fresh Product

Consistent final

product flow

cytometry profiles

across 3 at-scale

batches

• 3 Batches

• 11 Samples

Endocrine Purity Beta Cell Content Islet Cell Impurity

Source: Company data on file

CNTY-813 islets contain defined, terminally differentiated endocrine cell populations

Population Enriched Markers: β-cell: INS, NKX6.1; ⍺-cell: GCG,ARX; δ-cell: SST; Exocrine/Ductal: KRT19; FEV+ Islet Cell: FEV+SLC18A1+

Diff. Stage:

scRNAseq Cell Type Annotations scRNAseq Cell Cycle Annotations

• CNTY-813 manufacturing achieves a defined islet endocrine composition, with beta cells as the predominant population

• Data is consistent with cell cycle exit on par with primary islets by end of manufacture (>98% G1 phase identity)

CNTY-813 data represents four combined end-of-process samples

iPSC 1 2 3 4 5 6

Population (30,151 total) Frequency

β cells 66.3%

FEV+ Islet Cells 26.4%

⍺ cells 5.5%

δ cells 0.8%

Exocrine/Ductal 1.0%

CNTY-813 islet cells demonstrate robust glucose-responsive function

Nonclinical Potency

Glucose Stimulated Insulin Secretion Stimulation Index Total Insulin Content

Source: Company data on file

iPSC- Islets Primary Islets

10000

20000

30000

40000

uIU Insulin/ 1E6 Cells

2mM Glucose

20mM Glucose

∆GSIS

Mean +/- SD is shown in graphs

iPSC- Islets

Primary Islets

Glucose Stimualtion Index

(20mM glucose/ 2mM glucose) Glucose Stimulation Index

Allo-EvasionTM 5.0-edited CNTY-813 restored glucose control for >11 months

CNTY-813 islets rapidly restored normoglycemia in STZ-induced diabetic mice

Preclinical Potency

Non-Fasted Blood Glucose

0 20 40 60 80 100 120

100

200

300

400

500

600

Time (min)

Blood Glucose (mg/dL)

Diabetic Control Unedited CNTY Islet Cells

(5M) CNTY-813 (SRC)

(5M) - 12 weeks CNTY-813 (SRC)

(5M) - 49 weeks

Glucose

Control 0

125

150

175

2 5

250

275

325

350

375

100

200

300

400

500

600

Days Post Treatment

Blood Glucose (mg/dL)

No Treatment CNTY-813 (SRC)

(5M)

Unedited CNTY Islet Cells

(5M)

Normoglycemic Control

Glucose

Control

Glucose Tolerance Test

Mean +/- SEM Mean +/- SD

Source: Company data on file

STZ = Streptozotocin | SRC = Sub renal capsule implantation, Gray shaded area = normal blood glucose range

CNTY-813 grafts maintain endocrine identity with no evidence of tumorigenesis in mouse

models

Endocrine graft identity over time

INS+ (green)

CHGA+ (orange)

Merged (yellow)

Ki67+ (pink)

DAPI (blue)

INS: Insulin stain; CHGA: CHGA stain; Ki67: Stain for Ki67; DAPI:nuclear stain

2 weeks 4 weeks 8 weeks 24 weeks

✓ Endocrine graft morphology maintained

✓ No Ki67 increase or cyst formation

✓ No tumorigenesis observed in >140 mice with

>3-month follow up (>1B cells infused)

200µm

Source: Company data on file

Allo-EvasionTM 5.0 protected CNTY-813 from rejection in a humanized mouse model

Glucose Stimulation Index Glucose Tolerance Test (GTT)

(11 weeks post-islet infusion)

Reduced function

with PBMC

engraftment

Maintained function

with PBMC

engraftment

Allo-Evasion 5.0 maintained CNTY-813 Glucose Stimulated Insulin Secretion and GTT performance in vivo1

0 7 14 21 28 35 42 49

Days Post Transplant Glucose-Stimulated Insulin Secretion Index C( -peptide induction over baseline) Unedited Islets + PBMCs Unedited Islets

Allo-Rejection

0 7 14 21 28 35 42 49

Days Post Transplant Glucose-St mi ulated Insulin Secretion Index

(C-peptide induction over baseline) CNTY-813 Allo-Evasion 5.0 Islets + PBMCs CNTY-813 Allo-Evasion 5.0 Islets

Mean ± SEM

0 30 60 90 120

200

400

600

Time (min.) Blood Glucose (mg/dL)

Unedited Islets + PBMCs Unedited Islets

0 30 60 90 120

200

400

600

Time (min.) Blood Glucose (mg/dL)

Allo-Evasion 5.0 Islets + PBMCs Allo-Evasion 5.0 Islets

Mean ± SD

Source: Company data on file

1. Humanized mouse model includes functional human T cells without GvHD (MHC KO) and TgHuIL-15 to support functional NK cell engraftment and survival

Unedited

Islets

Allo-EvasionTM

5.0 Islets

Unedited

Islets

Allo-EvasionTM

5.0 Islets

CAR-iT Franchise: CD4+/CD8+

αβ CAR-iT-cell with Allo-Evasion 5.0

CNTY-308 is a CAR-iT targeting CD19 that aims to pair the characteristics of

autologous CAR-T with the convenience of an allogeneic CAR-T for the

treatment of autoimmune disease

Potential to address

significant unmet need

in autoimmunity with

allogeneic CAR iT cells

• CNTY-308 expected to enter clinic in 2026

• Autologous CAR T cell therapies are showing compelling clinical safety and

efficacy across a broad range of autoimmune diseases1

• Clinical data from B-cell-targeted cell therapies in autoimmune disease support

the MoA and development of CAR iT therapies

• CNTY-308 lays the groundwork for expansion of the CAR-iT franchise into other

diseases

CNTY-308 (CD19 CAR iT with Allo-EvasionTM 5.0)

1. Muller 2024 doi/full/10.1056/NEJMoa2308917; Nordmann-Gomes 2025 doi.org/10.1016/j.semarthrit.2025.152786

2. Gao 2025 EULAR Abstract DOI: 10.1016/j.ard.2025.05.396; Wang 2025 doi.org/10.1016/j.cell.2025.05.038

CNTY-308 is an iPSC-derived CD19-targeted CAR-iT intended for

B-cell-mediated disease

CNTY-308

• CD19-targeted CAR to target B-cells for cytotoxic depletion

– 4-1BB and CD3z co-stim domain to stimulate expansion on

target engagement

• Displays characteristics of autologous CAR-T cells1

✓ Highly proliferative upon target engagement

✓ Secretes cytokines (e.g., IL-2, IFNγ and TNFα)

✓ Cytotoxic effector function rapidly eliminates tumor cells

✓ Long-term persistence in vivo

✓ Eliminates CD19+ B-cells from healthy donors in vitro2

• Allo-Evasion 5.0 edits designed to include protection from

host T cell, NK cell, and humoral response

• Native ab TCR knock-out to eliminate the risk of GvHD

1. www.centurytx.com/wp-content/uploads/ASH_Heinze_iPSC-Derived-CD4-CD8-Final.pdf

2. Company data on file

3. IDP = IgG degrading enzyme

CD4+/CD8+ αβ iT-cell

• Self-supports with own target-mediated IL-2

• High functional persistence: kills for >10 rounds, persists in blood for 32+ days, controls

tumor after in vivo rechallenge

In preclinical studies, CNTY-308 cells are comparable to primary CAR-T cells

Source: Company data on file

≈

1’ CAR-T CNTY-308

IL-2 secretion (pg/mL)

≈

Requires exogenous IL-2/IL-15

Repeat killing (rounds)

Persistence in blood (days)

Tumor control after rechallenge

(in vivo)

~2,000

>10

Yes

~3,000

>10

Yes

Function

≈

CNTY–308 and

1’ CAR-T

In preclinical animal studies, Century iPSC-CAR-T cells controlled tumors,

persisted for ≥1 month, and retained cytotoxic capacity upon rechallenge

Source: Company data on file

• Disseminated Nalm6 model (1e5 cells infused)

• Effectors added 3 days post-tumor infusion

• 1’ CAR-T dose: 5e6 cells

• iPSC-CAR-T dose: 30e6 cells

• No added cytokine or small molecule support

• iPSC-CAR-T produced at phase 1 clinical scale

In vivo experimental details Complete tumor control

Measurable long-term persistence ≥1 mo Cytotoxicity maintained upon re-challenge with engrafted cells

Group 1: PBS only Group 2: 1' CAR−T Group 3: iPS−CAR−T

0 10 20 30 0 10 20 30 0 10 20 30

1e+07

1e+09

1e+11

Days Post−Effector Infusion

Luminescence (log axis)

Tumor

challenge

Tumor

challenge

Tumor

challenge

1e+06

1e+07

1e+08

1e+09

1e+10

0 10 20 30 40 Days Post−Effector Infusion

Luminescence (log axis)

Group

PBS only

1' CAR−T

iPS−CAR−T

1e+06

1e+07

1e+08

1e+09

1e+10

0 10 20 30 40

Days Post−Effector Infusion

min

e (lo

xis)

Class

PBS only

1' CAR−T

iPS−CAR−T

Group

PBS only

1' CAR−T

iPS−CAR−T

100

1000

PBS 1' CAR−T iPS−CAR−T Group

hCD45+ count per 100 uL whole blood

Group joined by lines

d7 d21

d35

Key

d27 tumor rechallenge

• iPSC-CAR-T persist 21 days post-infusion,

• iPSC-CAR-T detectable at day 35, 7 days post-tumor rechallenge (at day 28)

Tumor

challenge

Tumor

challenge

CNTY-308 robustly depleted B cells in vitro and in vivo

Source: Company data on file

In Vitro B Cell Depletion B Cell Depletion in Human PBMC Engrafted Mice

CD20

+ Cells/100um

2 Femur

Naive PBMC Alone PBMC + CNTY-308 CNTY-308 Alone

✱✱ ✱✱

✱✱

Bone Marrow

CD20

+ Cells/100um

2 Spleen

✱✱✱✱ ✱✱✱

✱✱✱✱

Spleen

4:1

2:1

1:1

.5:1

.25:1

.125:1

.0625:1

.03125:1

.015625:1

.0 781:1

0:1

100

T cell : PBMC ratio

Percent Killing of B Cells (%)

(MHCI+

,CD3-, CD19

, Blin

+cells)

SLE Donor 1 SLE Donor 2 SLE Donor 3

LN Donor 1

LN Donor 2

CNTY-308 cells efficiently kill B cells

from SLE and Lupus Nephritis donors

PBMC Alone PBMC + CNTY-308

Corporate Summary

Century Therapeutics: Advancing Curative Medicines Through Cell Engineering

The Cell Foundry: Enables scalable generation of

highly functional iPSC-derived therapies

Allo-EvasionTM 5.0: Leadership in immune-evasive

cell design

Integrated Know-How: Deep functional expertise

internally, integrated from discovery to

manufacturing and development

Foundational Platform Tech:

Engine to create and scale

cellular medicines

Targeting Functional Cures:

T1D and Autoimmune disease

Well Funded:

Multiple Anticipated Near-Term

Milestones

CNTY-813: iPSC-derived, immune-evasive islet

replacement therapy for type 1 diabetes

Islet replacement is clinically validated; CNTY-813 aims to

deliver this without chronic immunosuppression, at scale

Pipeline: Foundational technology powers:

• CNTY-308, an iPSC-derived, immune-evasive T cell

with potential across autoimmune disease

• Next-gen discovery programs across multiple cell types

and targets

Recent Funding

Oversubscribed $135M PIPE in early 2026 provides

runway into Q1 2029

Key Anticipated Near-Term Milestones

❑ CNTY-813 oral presentation at EASD 2026

❑ CNTY-813 IND submission expected 4Q 2026

❑ CNTY-308 expected in clinic in 2026

❑ Clinical data expected 2H 2027 for CNTY-813

Focused. Funded. Executing.

www.centurytx.com

GRAPHIC

Filename: tm2622911d1_ex99-2img001.jpg · Sequence: 8

Binary file (149423 bytes)

Download tm2622911d1_ex99-2img001.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img002.jpg · Sequence: 9

Binary file (371092 bytes)

Download tm2622911d1_ex99-2img002.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img003.jpg · Sequence: 10

Binary file (177004 bytes)

Download tm2622911d1_ex99-2img003.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img004.jpg · Sequence: 11

Binary file (92128 bytes)

Download tm2622911d1_ex99-2img004.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img005.jpg · Sequence: 12

Binary file (117477 bytes)

Download tm2622911d1_ex99-2img005.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img006.jpg · Sequence: 13

Binary file (66105 bytes)

Download tm2622911d1_ex99-2img006.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img007.jpg · Sequence: 14

Binary file (147535 bytes)

Download tm2622911d1_ex99-2img007.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img008.jpg · Sequence: 15

Binary file (166640 bytes)

Download tm2622911d1_ex99-2img008.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img009.jpg · Sequence: 16

Binary file (170082 bytes)

Download tm2622911d1_ex99-2img009.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img010.jpg · Sequence: 17

Binary file (165767 bytes)

Download tm2622911d1_ex99-2img010.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img011.jpg · Sequence: 18

Binary file (177792 bytes)

Download tm2622911d1_ex99-2img011.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img012.jpg · Sequence: 19

Binary file (149127 bytes)

Download tm2622911d1_ex99-2img012.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img013.jpg · Sequence: 20

Binary file (133481 bytes)

Download tm2622911d1_ex99-2img013.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img014.jpg · Sequence: 21

Binary file (176826 bytes)

Download tm2622911d1_ex99-2img014.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img015.jpg · Sequence: 22

Binary file (129215 bytes)

Download tm2622911d1_ex99-2img015.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img016.jpg · Sequence: 23

Binary file (120731 bytes)

Download tm2622911d1_ex99-2img016.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img017.jpg · Sequence: 24

Binary file (136736 bytes)

Download tm2622911d1_ex99-2img017.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img018.jpg · Sequence: 25

Binary file (158637 bytes)

Download tm2622911d1_ex99-2img018.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img019.jpg · Sequence: 26

Binary file (105823 bytes)

Download tm2622911d1_ex99-2img019.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img020.jpg · Sequence: 27

Binary file (149210 bytes)

Download tm2622911d1_ex99-2img020.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img021.jpg · Sequence: 28

Binary file (177049 bytes)

Download tm2622911d1_ex99-2img021.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img022.jpg · Sequence: 29

Binary file (145798 bytes)

Download tm2622911d1_ex99-2img022.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img023.jpg · Sequence: 30

Binary file (49404 bytes)

Download tm2622911d1_ex99-2img023.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img024.jpg · Sequence: 31

Binary file (142708 bytes)

Download tm2622911d1_ex99-2img024.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img025.jpg · Sequence: 32

Binary file (145411 bytes)

Download tm2622911d1_ex99-2img025.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img026.jpg · Sequence: 33

Binary file (125302 bytes)

Download tm2622911d1_ex99-2img026.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img027.jpg · Sequence: 34

Binary file (191495 bytes)

Download tm2622911d1_ex99-2img027.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img028.jpg · Sequence: 35

Binary file (124617 bytes)

Download tm2622911d1_ex99-2img028.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img029.jpg · Sequence: 36

Binary file (60805 bytes)

Download tm2622911d1_ex99-2img029.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img030.jpg · Sequence: 37

Binary file (177222 bytes)

Download tm2622911d1_ex99-2img030.jpg

GRAPHIC

Filename: tm2622911d1_ex99-2img031.jpg · Sequence: 38

Binary file (37645 bytes)

Download tm2622911d1_ex99-2img031.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 40

v3.26.1

Cover

Aug. 12, 2026

Entity Addresses [Line Items]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 12, 2026

Entity File Number

001-40498

Entity Registrant Name

Century Therapeutics, Inc.

Entity Central Index Key

0001850119

Entity Tax Identification Number

84-2040295

Entity Incorporation, State or Country Code

Entity Address, Address Line One

North 38th Street

Entity Address, Address Line Two

12th Floor

Entity Address, City or Town

Philadelphia

Entity Address, State or Province

Entity Address, Postal Zip Code

19104

City Area Code

267

Local Phone Number

817-5790

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.0001 per share

Trading Symbol

IPSC

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Former Address [Member]

Entity Addresses [Line Items]

Entity Address, Address Line One

North 38th Street

Entity Address, Address Line Two

11th Floor

Entity Address, City or Town

Philadelphia

Entity Address, State or Province

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressesLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: